Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy.

Abstract

Aim: Clinical features of esophageal cancer (EC) patients have poor prognostic power. Thus, it is paramount to discover biomarkers that can allow a more accurate survival prediction. Methods: To detect genetic variants associated with survival, DNA from 120 patients treated with cisplatin-based neoadjuvant therapy were genotyped using drug metabolism enzymes and transporters array. Results: We identified two variants: the rs2038067 in PPARD (p = 0.0004) and the rs683369 (F160L) in SLC22A1 (p = 0.001). Their prognostic power was greater than that of clinical stage alone (p = 0.017) and comparable to that of response to neoadjuvant therapy (p = 0.71). Interestingly, the prognostic accuracy of response models increased significantly when genetic variables were included (p = 0.003). Conclusion: Our data, though preliminary, strengthen the potential utility of germline variants for a better-tailored management of EC patients.

• Authors: Enrica Rumiato, Elisa Boldrin, Sandro Malacrida, Giorgio Battaglia, Vanna Chiarion Sileni, Alberto Ruol, Alberto Amadori, Daniela Saggioro
• Journal: Pharmacogenomics (Pharmacogenomics) Vol. 21 Issue 6 Pg. 393-402 (04 2020) ISSN: 1744-8042 [Electronic] England
• PMID: 32285752 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Organic Cation Transporter 1
• PPAR delta
• Cisplatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Cisplatin (therapeutic use)
• Esophageal Neoplasms (drug therapy, genetics, mortality)
• Female
• Follow-Up Studies
• Genetic Variation (genetics)
• Humans
• Male
• Middle Aged
• Neoadjuvant Therapy (methods)
• Organic Cation Transporter 1 (genetics)
• PPAR delta (genetics)
• Survival Rate (trends)